全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：LCZ696 936623-90-4LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart
產(chǎn)品型號：abs47027992廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-12訪 問 量：576產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細介紹
| 品牌 | absin | CAS | 936623-90-4 |
|---|---|---|---|
| 分子式 | C24H29N5O3.C24H29NO5.5/2H2O.3Na | 純度 | ≥98% |
| 分子量 | 915.98 | 貨號 | abs47027992 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is an orally bioavailable | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
LCZ696 936623-90-4
| 產(chǎn)品描述 | |
| 描述 | LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3. |
| 純度 | ≥98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 奧帕曲拉；纈sha坦；Sacubitril；valsartan |
| 外觀 | white powder |
| 可溶性/溶解性 | DMSO : 28 mg/mL (30.6 mM) Ethanol : 9 mg/mL (9.82 mM), warmed Water : 92 mg/mL (100.4 mM) |
| 生物活性 | |
| 靶點 | RAAS |
| In vitro(體外研究) | LCZ696 is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and AHU377, a neprilysin inhibitor (1:1 ratio). |
| In vivo(體內(nèi)研究) | LCZ696 exerts a blood pressure lowering effect. Blood pressure reduction by LCZ696 is associated with a significant increase in urinary sodium excretion and sympathetic activity suppression. LCZ696 significantly ameliorates cardiac hypertrophy and inflammation, coronary arterial remodeling, and vascular endothelial dysfunction in high-salt loaded SHRcp compared with valsartan. The neprilysin inhibitor component of LCZ696, LBQ657, inhibits hypertrophy but not fibrosis. The angiotensin receptor blocker component of LCZ696, valsartan inhibits both hypertrophy and fibrosis. Dual valsartan+LBQ augment the inhibitory effects of valsartan and the highest doses completely abrogate angiotensin II-mediated effects. Pre-treatment with LCZ696 reduces the ischemic area. The decrease in cerebral blood flow in the peripheral region of the ischemic area is significantly attenuated by pre-treatment with LCZ696. LCZ696 pre-treatment significantly decreases the increase of superoxide anion production in the cortex on the ischemic side. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Cardiovascular CancerCancer Metabolism CancerTumor biomarkers NeuroscienceEndocrine system Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：